Resources from the same session
2608 - Quality-of-life (QoL) results from RAINFALL: A randomized, double-blind, placebo (PL)-controlled phase 3 study of cisplatin (Cis) plus capecitabine (Cape) or 5FU with or without ramucirumab (RAM) as first-line therapy for metastatic gastric or gastroesophageal junction (G-GEJ) cancer
Presenter: Ian Chau
Session: Poster Discussion session -Gastrointestinal, non-colorectal
Resources:
Abstract
Slides
1905 - A phase 3 study of nivolumab (Nivo) in previously treated advanced gastric or gastric esophageal junction (G/GEJ) cancer (ATTRACTION-2): Two-years update data.
Presenter: Taroh Satoh
Session: Poster Discussion session -Gastrointestinal, non-colorectal
Resources:
Abstract
5236 - Influence of sex on chemotherapy efficacy and toxicity in oesophagogastric (OG) cancer: a pooled analysis of 4 randomised trials
Presenter: Michael Davidson
Session: Poster Discussion session -Gastrointestinal, non-colorectal
Resources:
Abstract
Poster Discussion session -Gastrointestinal, non-colorectal - Invited Discussant 616PD, 617PD and 619PD_PR
Presenter: Florian Lordick
Session: Poster Discussion session -Gastrointestinal, non-colorectal
Resources:
Slides
Webcast
3339 - Progression-free survival and recurrence results for AGITG DOCTOR. Pre-op cisplatin, 5FU & DOCetaxel +/-radioTherapy after poOR early response to cisplatin & 5FU for resectable oesophageal adenocarcinoma.
Presenter: Andrew Barbour
Session: Poster Discussion session -Gastrointestinal, non-colorectal
Resources:
Abstract
2665 - Influence of enteral nutrition on nutritional status, treatment toxicities, and short-term outcomes in esophageal carcinoma patients treated with concurrent chemoradiotherapy: a prospective, multicenter, randomized controlled study
Presenter: Tao Li
Session: Poster Discussion session -Gastrointestinal, non-colorectal
Resources:
Abstract
4283 - Phase 2 trial of tepotinib vs sorafenib in Asian patients (pts) with advanced hepatocellular carcinoma (HCC)
Presenter: Baek-Yeol Ryoo
Session: Poster Discussion session -Gastrointestinal, non-colorectal
Resources:
Abstract
1812 - Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated alpha-fetoprotein (AFP) following first-line sorafenib: patient reported outcome results across two phase 3 studies (REACH-2 and REACH)
Presenter: Andrew Zhu
Session: Poster Discussion session -Gastrointestinal, non-colorectal
Resources:
Abstract
Poster Discussion session -Gastrointestinal, non-colorectal - Invited Discussant 621PD, 622PD and One LBA TBC
Presenter: Ann-Lii Cheng
Session: Poster Discussion session -Gastrointestinal, non-colorectal
Resources:
Slides
Webcast
3652 - Updated results from a phase II study of infigratinib (BGJ398), a selective pan-FGFR kinase inhibitor, in patients with previously treated advanced cholangiocarcinoma containing FGFR2 fusions
Presenter: Milind Javle
Session: Poster Discussion session -Gastrointestinal, non-colorectal
Resources:
Abstract